Pfizer Prices Bosulif With Eye Towards Leveling CML Playing Field
This article was originally published in The Pink Sheet Daily
Pfizer enters crowded competition for previously treated Ph+ chronic myelogenous leukemia with the newly approved bosutinib, but the firm hopes having a comparable price will level the playing field.
You may also be interested in...
Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial
Pfizer’s NDA for dual Src and Abl inhibitor bosutinib in previously-treated Philadelphia chromosome-positive CML bypassed the failed first-line Phase III BELA trial. In Europe, BELA is the basis of a pending front-line CML application.
Publisher's Spotlight: Entry Reminder For The Citeline Awards
The deadline is approaching for submissions to the 2023 Citeline Awards; gain recognition for your clinical research team, real world evidence project, diversity and inclusion efforts, and more.
Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus
Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.